Assess whether the primary endpoint will survive FDA scrutiny (c486c4)

SITUATION After a DSMB note on an imbalance that is not yet a signal, advisory-committee question list that exposes a weak secondary endpoint is what pediatric-plan strategist can touch in a biologics company planning a biosimilar pathway. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this Pharmacovigilance file.

DECISION Pediatric-plan strategist in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; advisory-committee question list that exposes a weak secondary endpoint already has the discriminator after a DSMB note on an imbalance that is not yet a signal. 2. Keep Pause the pathway in force until advisory-committee question list that exposes a weak secondary endpoint is completed after a DSMB note on an imbalance that is not yet a signal for pediatric-plan strategist. 3. Treat advisory-committee question list that exposes a weak secondary endpoint as Escalate safety review because both readings appear after a DSMB note on an imbalance that is not yet a signal. 4. Refuse a Pharma & Life Sciences close: pediatric-plan strategist does not have the decision the primary endpoint will turns on in advisory-committee question list that exposes a weak secondary endpoint.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a DSMB note on an imbalance that is not yet a signal. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 4. For this Pharma & Life Sciences Pharmacovigilance file, read advisory-committee question list that exposes a weak secondary endpoint against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move the primary endpoint will for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (advisory-committee question list that exposes a weak secondary endpoint after a DSMB note on an imbalance that is not yet a signal). Lead with the Pharma & Life Sciences option advisory-committee question list that exposes a weak secondary endpoint can support after a DSMB note on an imbalance that is not yet a signal, then the two facts that force it, then the Monday action for pediatric-plan strategist in a biologics company planning a biosimilar pathway.